Table 2.
Recommended approach of RA treatment with DMARDs
| • One or more DMARDs (preferably, a small molecule and a biologic) |
| • Principal short term objectives are symptom alleviation and prevention of joint damage |
| • Long term goals are to achieve remission or at least LDA |
| • Therapeutic efficacy should be assessed regularly and adjusted if response is low or absent |
| • No progression of radiologic features of joint destruction should be insured |